154 related articles for article (PubMed ID: 37527977)
1. Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
Mahdi D; Spiers J; Rampotas A; Polverelli N; McLornan DP
Br J Haematol; 2023 Oct; 203(2):169-181. PubMed ID: 37527977
[TBL] [Abstract][Full Text] [Related]
2. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
3. Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN; Gangat N
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
[TBL] [Abstract][Full Text] [Related]
4. Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.
Saha C; Attwell L; Harrison CN; McLornan DP
Blood Rev; 2022 Sep; 55():100947. PubMed ID: 35241294
[TBL] [Abstract][Full Text] [Related]
5. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
6. Accelerated and Blast Phase Myeloproliferative Neoplasms.
Jain T; Rampal RK
Hematol Oncol Clin North Am; 2021 Apr; 35(2):325-335. PubMed ID: 33641872
[TBL] [Abstract][Full Text] [Related]
7. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It.
Patel AA; Odenike O
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):303-309. PubMed ID: 36907766
[TBL] [Abstract][Full Text] [Related]
8. MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.
He Z; Wang B; Chen L; Huang Y; Wang H; Yang M; Xiao X; Lu Y; Chen J; Wu Y
Medicine (Baltimore); 2018 Nov; 97(46):e13220. PubMed ID: 30431598
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
[No Abstract] [Full Text] [Related]
10. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.
Pardanani A; Lasho TL; Finke CM; Mai M; McClure RF; Tefferi A
Leukemia; 2010 Jun; 24(6):1146-51. PubMed ID: 20410924
[TBL] [Abstract][Full Text] [Related]
11. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
Kundranda MN; Tibes R; Mesa RA
Curr Hematol Malig Rep; 2012 Mar; 7(1):78-86. PubMed ID: 22170483
[TBL] [Abstract][Full Text] [Related]
12. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
Bewersdorf JP; Rampal RK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
[TBL] [Abstract][Full Text] [Related]
13. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.
Odenike O
Blood; 2018 Nov; 132(22):2339-2350. PubMed ID: 30333119
[TBL] [Abstract][Full Text] [Related]
14. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Szuber N; Begna KH; Patnaik MM; Gangat N; Pardanani A; Tefferi A
Blood Adv; 2018 Feb; 2(4):370-380. PubMed ID: 29467191
[TBL] [Abstract][Full Text] [Related]
15. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
Pardanani A; Lasho T; Finke C; Oh ST; Gotlib J; Tefferi A
Leukemia; 2010 Oct; 24(10):1713-8. PubMed ID: 20724988
[TBL] [Abstract][Full Text] [Related]
16. Management of advanced phase myeloproliferative neoplasms.
Marcellino B; Mascarenhas J
Clin Adv Hematol Oncol; 2019 Jul; 17(7):405-411. PubMed ID: 31449507
[TBL] [Abstract][Full Text] [Related]
17. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.
Iurlo A; Cattaneo D; Gianelli U
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013941
[TBL] [Abstract][Full Text] [Related]
18. Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms.
Abruzzese E; Niscola P
Expert Rev Hematol; 2020 Dec; 13(12):1349-1359. PubMed ID: 33226274
[No Abstract] [Full Text] [Related]
19. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A; Alkhateeb H; Gangat N
Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and predictors of survival in blast phase myeloproliferative neoplasms.
Lancman G; Brunner A; Hoffman R; Mascarenhas J; Hobbs G
Leuk Res; 2018 Jul; 70():49-55. PubMed ID: 29807273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]